/Authentication report on the annual storage, management and actual use of funds raised by Aiwei Technology

NEWS

Authentication report on the annual storage, management and actual use of funds raised by Aiwei Technology

Shanghai Stock Exchange

2026/04/29

1. Restrictions on report users and purpose of use

This assurance report is only used for disclosure in the annual report of Aiwei Technology Company and shall not be used for any other purpose. We agree to use this assurance report as a necessary document for the annual report of Aiwei Technology Company, and submit it together with other documents and disclose it to the public.

2. Management Responsibilities

The responsibility of the management of Aiwei Technology Company is to provide true, legal and complete relevant information, in accordance with the "Regulations on the Supervision of Funds Raised by Listed Companies" (China Securities Regulatory Commission Announcement [2025] No. 10) and the "Shanghai Stock Exchange's Self-Regulatory Supervision Guidelines for Companies Listed on the Science and Technology Innovation Board No. 1 - Standardized Operations (Revised in May 2025)" (Shanghai Securities Regulatory Commission [2025] 69 No.), prepare a "Special Report on the Annual Deposit, Management and Actual Use of Raised Funds" and ensure that its content is true, accurate and complete, and does not contain false records, misleading statements or major omissions.

3. Responsibilities of Certified Public Accountants

Our responsibility is to independently provide assurance conclusions on the above-mentioned report prepared by the management of Aiwei Technology Company based on the implementation of assurance work.

Page 1 of 17

4. Work Overview

We performed the assurance business in accordance with the Chinese Professional Standards for Certified Public Accountants. The Practice Standards for Certified Public Accountants in China require us to plan and implement assurance work to obtain reasonable assurance as to whether the information subject to assurance does not contain material misstatements. During the attestation process, we implemented procedures we considered necessary, including verification of accounting records. We believe that our assurance work provides a reasonable basis for our opinion.

5. Assurance conclusion

We believe that the 2025 "Special Report on the Annual Deposit, Management and Actual Use of Raised Funds" prepared by the management of Aiwei Technology Company complies with the "Supervision Rules for Raised Funds by Listed Companies" (China Securities Regulatory Commission Announcement [2025] No. 10) and the "Self-Discipline Supervision Guidelines for Companies Listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange No. 1 - Standardized Operations" (May 2025) The provisions of "Monthly Revision" (Shanghai Securities Fa [2025] No. 69) truthfully reflect the actual storage, management and actual use of funds raised by Aiwei Technology Company in 2025.

Tianjian Certified Public Accountants (Special General Partnership) Chinese Certified Public Accountant:

Hangzhou, China Chinese Certified Public Accountant:

April 28, 2026

Page 2 of 17

Aiwei Technology Co., Ltd.

Special report on the annual storage, management and actual use of raised funds

In accordance with the provisions of the "Supervision Rules for Funds Raised by Listed Companies" (China Securities Regulatory Commission Announcement [2025] No. 10) and the "Shanghai Stock Exchange's Self-Regulatory Supervision Guidelines for Companies Listed on the Science and Technology Innovation Board No. 1 - Standardized Operations (Revised in May 2025)" (Shanghai Securities Regulatory Commission [2025] No. 69), a special explanation of the storage, management and actual use of the company's 2025 raised funds is as follows.

1. Basic situation of raised funds

(1) Actual amount of funds raised and time of fund arrival

According to the China Securities Regulatory Commission's "Reply on Approving the Registration of the Initial Public Offering of Aiwei Technology Co., Ltd." (CSRC Permit [2021] No. 1628), the company, through the lead underwriter West Securities Co., Ltd. (hereinafter referred to as West Securities), used the price inquiry method to publicly issue 17,000,000 RMB ordinary shares (A shares) to the public at an issue price of RMB 14.71 per share, raising a total of funds 250.070 million yuan, and the raised funds after deducting underwriting and recommendation fees of 22.5055 million yuan (including value-added tax) are 227.5645 million yuan, which has been remitted to the company's raised funds supervision account by the lead underwriter Western Securities on June 9, 2021. In addition, after deducting the online issuance fees, prospectus printing fees, reporting accountant fees, lawyer fees and other new external expenses directly related to the issuance of equity securities of 19.2586 million yuan (excluding value-added tax), and adding the value-added tax of 1.2739 million yuan for the underwriting and sponsor fees of this issuance, the company's net raised funds this time is 209.5798 million yuan. The above-mentioned receipt of funds raised has been verified by Tianjian Accounting Firm (Special General Partnership), which issued a "Capital Verification Report" (Tianjianyan [2021] No. 2-10).

(2) Basic information on raised funds

Amount unit: RMB 10,000 Issuance name 2021 initial public offering of shares

The time for receipt of raised funds is June 9, 2021

This reporting period is from January 1, 2025 to December 31, 2025

Project amount

Total funds raised 25,007.00, including: excess amount of funds raised

Page 3 of 17

Less: Direct payment of issuance expenses 4,049.02

Net raised funds 20,957.98 minus:

Amount used in previous years 8,675.74 Amount used this year 1,815.86 Permanent supplementary amount 8,862.69 Cash management amount 2,000.00 Add:

Interest income from raised funds 1,365.31

Balance of raised funds at the end of the reporting period 969.00

2. Management of raised funds

(1) Management of raised funds

In order to standardize the management and use of raised funds, improve the efficiency and effectiveness of fund use, and protect the rights and interests of investors, the company complies with the "Company Law of the People's Republic of China", "Securities Law of the People's Republic of China", "Supervisory Rules for Funds Raised by Listed Companies" (China Securities Regulatory Commission Announcement [2025] No. 10) and the "Shanghai Stock Exchange Science and Technology Innovation Board" Municipal Company Self-Regulation Guidelines No. 1 - Standardized Operations (Revised in May 2025)" (Shangzhengfa [2025] No. 69) and other relevant laws, regulations and normative documents, and based on the actual situation of the company, the "Administrative Measures for Fund Raising by Aiwei Technology Co., Ltd." (hereinafter referred to as the "Administrative Measures") were formulated. According to the "Administrative Measures", the company deposits the raised funds in a special account and sets up a special account for raised funds in the bank. After the company's listing, the company, together with the sponsor Western Securities, signed the "Raising Funds" with Shanghai Pudong Development Bank Co., Ltd. Changsha Branch, Industrial Bank Co., Ltd. Changsha Branch, and Changsha Bank Co., Ltd. Hanpu Branch. "Golden Three-Party Supervision Agreement"; the company, together with Western Securities and its wholly-owned subsidiary Hunan Aiwei Medical Technology Co., Ltd. (hereinafter referred to as Aiwei Medical), signed a "Four-Party Supervision Agreement on Raised Funds" with Industrial Bank Co., Ltd. Changsha Branch and Shanghai Pudong Development Bank Co., Ltd. Changsha Branch respectively, clarifying the rights and obligations of all parties.

On April 27, 2022, the fifth meeting of the company's fourth board of directors and the fifth meeting of the fourth board of supervisors reviewed and approved the "Proposal on Changing the Special Account for Partial Raised Funds", agreeing to change part of the special account for raised funds: agreeing to cancel the company's original special account for raised funds at the Changsha Xiangfu Road Branch of Industrial Bank Co., Ltd., and transfer the raised funds to All principal and interest balances in the capital account are transferred to the company's newly opened special account for raised funds at the Hanpu Branch of Changsha Bank Co., Ltd.; it is agreed to cancel the special account for raised funds established by Aiwei Medical at the Changsha Xiangfu Road Branch of Industrial Bank Co., Ltd., and transfer the principal and interest balance in the raised funds account to Aiwei Medical's newly opened account at the Hanpu Branch of Changsha Bank Co., Ltd.

Page 4 of 17

special account for raised funds. On April 28, 2025, the second meeting of the company's fifth board of directors and the second meeting of the fifth board of supervisors reviewed and approved the "Proposal on the Change, Closing and Extension of Investment Projects with Raised Funds and the Permanent Replenishment of Working Capital with the Surplus Raised Funds", and agreed to "technological transformation and production capacity of the production base of medical testing equipment and supporting reagent consumables" The total amount of investment in the "Expansion Project" was adjusted and the project was closed. It was agreed to cancel the two special accounts for raised funds originally established by the company at Changsha Houjiatang Branch of Shanghai Pudong Development Bank Co., Ltd., and to transfer all the remaining raised funds and financial management income in the special raised funds account to its own capital account for permanent supplementary working capital. As of December 31, 2025, the company has signed a "Tripartite Supervision Agreement for Raised Funds" with Changsha Bank Co., Ltd. Hanpu Branch and Western Securities and opened a special account for raised funds; the company has signed a "Four-Party Supervision Agreement for Raised Funds" with Aiwei Medical, Changsha Bank Co., Ltd. Hanpu Branch and Western Securities and opened a special account for raised funds.

There are no major differences between the aforementioned regulatory agreement and the Shanghai Stock Exchange regulatory agreement template, and the Company has strictly complied with it when using the raised funds.

(2) Storage of raised funds

As of December 31, 2025, the company has 3 special accounts for raised funds. The deposit status of raised funds is as follows:

Amount unit: RMB 10,000 Issuance name 2021 initial public offering of shares

The time for receipt of raised funds is June 9, 2021

Account name Opening bank Bank account number Ending balance Account status Aiwei Technology Co., Ltd. Changsha Bank Co., Ltd.

810000041525000005 117.59 In Use Co., Ltd. Sihanpu Branch

Aiwei Technology Co., Ltd. Changsha Bank Co., Ltd.

810000041525000007 851.41 In Use Co., Ltd. Sihanpu Branch

Hunan Aiwei Medical Changsha Bank Co., Ltd.

810000001666000002 - Not yet used Technology Co., Ltd. Sihanpu Branch

Total 969.00

3. Actual use of funds raised this year

(1) Comparison table of fund usage of investment projects with raised funds

For a comparison table on the use of raised funds, please see Appendix 1 of this report.
Explanation of abnormal situations in investment projects with raised funds

There were no abnormal situations in the investment projects raised by the Company.

Explanation of situations where the benefits of investment projects with raised funds cannot be separately calculated

Page 5 of 17

The company's new product research and development and innovation capability improvement projects themselves do not directly generate economic benefits, and the benefits cannot be calculated separately. After the project is completed, the benefits will mainly be reflected in the substantial improvement of the company's overall R&D strength and innovation capabilities, which will help the company develop new products and services, reduce R&D costs, and improve the company's overall core competitiveness.

The company's marketing network upgrade and remote operation and maintenance service platform construction project itself does not directly generate economic benefits. After the project is completed, the benefits will mainly be reflected in the further improvement of the company's marketing network system. At the same time, the new remote operation and maintenance service platform will greatly improve the company's after-sales service efficiency, reduce the company's product operation and maintenance costs, and enhance the intelligent level of the company's medical diagnostic products and services, which will help further expand the company's brand influence and consolidate the company's market competitive position.

(2) Advance investment and replacement of investment projects

Amount unit: RMB 10,000 Issuance name 2021 initial public offering of shares

The time for receipt of raised funds is June 9, 2021

The board of directors considers the total investment amount of raised funds [note that the pre-replacement of self-raised funds is completed

Replacement Amount Passed Date [Note Investment Project 1] Investment Amount Date

2]Medical testing equipment and

Supporting reagents and consumables

8,159.08 1,673.43 1,673.43 2021.9.03

Technical transformation of production base

and capacity expansion projects

New product research and development and innovation 2021.7.12

7,287.30 154.04 154.04 2021.8.13

New capability improvement project

Marketing network upgrade and

Remote operation and maintenance service platform 5,511.60 268.94 268.94 2021.8.9

Taiwan construction project

Total 20,957.98 2,096.41 2,096.41

[Note 1] The total investment amount is the total committed investment amount of raised funds before adjustment

[Note 2] According to the "Proposal on Using Raised Funds to Replace Self-raised Funds Pre-invested in Fund-raising Projects and Issue Fees Paid" reviewed and approved by the company at the 13th meeting of the third board of directors on July 12, 2021, the company also used raised funds of RMB 371,500 to replace self-raised funds that have paid issuance fees.

(3) Cash management of idle raised funds and investment in related products

Review of cash management of raised funds

Amount unit: RMB 10,000 Issuance name 2021 initial public offering of shares

The time for receipt of raised funds is June 9, 2021

Page 6 of 17

Planned cash proceeds Planned cash proceeds Board of Directors review

Plan start date Plan end date Amount to be managed How to manage Expiration date

Safe for purchase

13,000.00 2024.7.5 2025.7.2 2024.7.5 High performance and guaranteed capital

Requirements and good liquidity

3,800.00 2025.7.3 2026.7.2 Cash management assets on 2025.7.3

product

Cash management details of raised funds

Amount unit: RMB 10,000

Issue Name 2021 Initial Public Offering of Shares

The time for receipt of raised funds is June 9, 2021

Entrusted product Product Purchase Start End Return Not yet returned Estimated annualized interest entrusting party

Bank Name Type Amount Date Date Date Amount Rate of Interest Amount

2024 No. 812

Changsha bank stocks structural

Future company structural 500.00 2024.10.14 2025.1.13 2025.1.13 1.54%-2.29% 2.54 limited company deposits

Deposit

Liduoduo company is stable

Shanghai Pudong Fading 24JG3539

structural

Development Bank shares period (3-month view 5,000.00 2024.10.31 2025.1.24 2025.1.24 0.85%-2.25% 23.92

Deposit

Ltd. (up) RMB pair

public structured deposits

2024 No. 853

Changsha bank stocks structural

Future company structural 1,750.00 2024.10.22 2025.1.20 2025.1.20 1.54%-3.07% 6.65 limited company deposits

Deposit

2024 No. 854

Changsha bank stocks structural

Future company structural 1,650.00 2024.10.22 2025.1.20 2025.1.20 1.54%-3.07% 12.49 limited company deposits

Aiwei Technology Deposit

Co., Ltd. No. 920, 2024

Changsha bank stocks structural

Company Period Company Structural 1,200.00 2024.11.13 2025.2.11 2025.2.11 1.29%-3.03% 3.82 Limited Company Deposits

Deposit

2024 No. 919

Changsha bank stocks structural

Future company structural 1,500.00 2024.11.13 2025.2.11 2025.2.11 1.29%-3.03% 11.21 limited company deposits

Deposit

2024 No. 920

Changsha bank stocks structural

Future company structural 450.00 2024.11.13 2025.2.11 2025.2.11 1.29%-3.03% 1.43 limited company deposits

Deposit

2024 No. 919

Changsha bank stocks structural

Future company structural 550.00 2024.11.13 2025.2.11 2025.2.11 1.29%-3.03% 4.11 limited company deposits

Deposit

2025 No. 032

Changsha bank stocks structural

Future company structural 150.00 2025.1.16 2025.4.16 2025.4.16 1.29%-2.67% 0.99 limited company deposit

Deposit

Page 7 of 17

2025 No. 031

Changsha bank stocks structural

Future company structural 150.00 2025.1.16 2025.4.16 2025.4.16 1.29%-2.67% 0.48 limited company deposits

Liduoduo company is stable

Set 25JG3040

Shanghai Pudong

Period (3 months early) Structural development bank shares 3,000.00 2025.1.26 2025.4.25 2025.4.25 0.85%-2.20% 6.38

Bird money) RMB Deposit Co., Ltd.

Structural existence

money

2025 No. 086

Changsha bank stocks structural

Future company structural 1,750.00 2025.1.24 2025.4.24 2025.4.24 1.29%-2.67% 5.57 limited company deposits

2025 No. 087

Changsha bank stocks structural

Future company structural 1,650.00 2025.1.24 2025.4.24 2025.4.24 1.29%-2.67% 10.86 limited company deposits

2025 No. 146

Changsha bank stocks structural

Future company structural 1,300.00 2025.2.14 2025.5.15 2025.5.15 1.24%-2.96% 9.49 limited company deposits

2025 No. 145

Changsha bank stocks structural

Future company structural 1,400.00 2025.2.14 2025.5.15 2025.5.15 1.24%-2.96% 4.28 limited company deposits

2025 No. 146

Changsha bank stocks structural

Future company structural 530.00 2025.2.14 2025.5.15 2025.5.15 1.24%-2.96% 3.87 limited company deposits

2025 No. 145

Changsha bank stocks structural

Future company structural 470.00 2025.2.14 2025.5.15 2025.5.15 1.24%-2.96% 1.44 limited company deposits

Liduoduo company is stable

Set 25JG3138

Shanghai Pudong

Period (monthly compound interest) Structural development bank shares 1,000.00 2025.4.1 2025.4.30 2025.4.30 0.85%-2.45% 1.97

13-Issue Special Contribution Deposit Co., Ltd.

B) RMB to corporate

structured deposits

Liduoduo company is stable

Set 25JG3176

Shanghai Pudong

Period (monthly rolling profit) Structural development bank shares 3,000.00 2025.5.6 2025.5.30 2025.5.30 0.85%-2.45% 4.50

14 Period Special Contribution Deposit Co., Ltd.

A) RMB to corporate

structured deposits

Company No. 2025

Issue 493 (Profit

Changsha bank stocks structural

Cumulative) (new customers/3,600.00 2025.5.9 2025.6.9 2025.6.9 1.24%-2.05% 6.27 Co., Ltd. Deposit and salary distribution special

enjoy)

Page 8 of 17 Liduoduo Company is stable

Set 25JG3178

Shanghai Pudong

Period (monthly rolling profit structural

Development Bank Shares 1,000.00 2025.5.6 2025.5.30 2025.5.30 0.85%-2.25% 1.37 14-period acceptance payment) Deposits

Ltd.

RMB to public settlement

structural deposits

2025 No. 644

Changsha bank stocks structural

Future company structural 950.00 2025.6.16 2025.6.16 2025.6.16 0.95%-2.82% 2.25 limited company deposits

Deposit

2025 No. 643

Changsha bank stocks structural

Future company structural 1,050.00 2025.6.16 2025.6.16 2025.6.16 0.95%-2.82% 7.38 limited company deposits

Deposit

2025 No. 789

Changsha bank stocks structural

Future company structural 295.00 2025.7.11 2025.10.17 2025.10.17 0.9%-2.47% 0.71 limited liability company deposit

Deposit

2025 No. 788

Changsha bank stocks structural

Future company structural 305.00 2025.7.11 2025.10.17 2025.10.17 0.9%-2.47% 2.02 limited company deposits

Deposit

2025 No.

Changsha bank stocks structural

1148th company settlement 1,025.00 2025.9.29 2025.12.29 2025.12.29 0.95%-2.63% 6.72 limited company deposits

structural deposits

2025 No.

Changsha bank stocks structural

1149th company settlement 975.00 2025.9.29 2025.12.29 2025.12.29 0.95%-2.63% 2.31 limited company deposits

structural deposits

Changsha Bank 2025

Changsha bank stocks structural

Issue 1359 of the year 205.00 2025.11.17 2026.2.25 2026.2.25 205.00 0.95%-2.63% Co., Ltd. deposit

structured deposits

Changsha Bank 2025

Changsha bank stocks structural

Issue 1360 of the year 195.00 2025.11.17 2026.2.25 2026.2.25 195.00 0.95%-2.63% Co., Ltd. deposit

structured deposits

Changsha Bank 2025

Changsha bank stocks structural

Issue 1619 of the year 700.00 2025.12.31 2026.4.3 2026.4.3 700.00 0.95%-2.63% Co., Ltd. deposit

structured deposits

Changsha Bank 2025

Changsha bank stocks structural

Issue 1620 of the year 900.00 2025.12.31 2026.4.3 2026.4.3 900.00 0.95%-2.63% Co., Ltd. deposit

structured deposits

Total 38,200.00 2,000.00 145.03

(4) Use of raised funds to permanently replenish working capital

Amount unit: RMB 10,000

Issue Name 2021 Initial Public Offering of Shares

The time for receipt of raised funds is June 9, 2021

Page 9 of 17 New Product Research and Development and 2026.12.

R&D Not suitable for improving innovation capabilities Yes 7,287.30 7,508.78 7,508.78 1,151.74 5,760.54 -1,748.24 76.72 31 Not applicable No

Project use

Project [Note 1]

Marketing network upgrade Marketing

2026.12.

Not comfortable with remote operation and maintenance services

Yes 5,511.60 1,966.57 1,966.57 647.05 1,617.40 -349.17 82.24 31 Not applicable No Used for service platform construction projects

[Note 1]

Project

Total - - 20,957.98 12,634.43 12,634.43 1,815.86 10,491.60 -2,142.83 - - - -

As of December 31, 2025, due to changes in the upstream and downstream market environment, the company has been continuously optimizing and improving work such as R&D project planning, market network layout, and reasons why brand promotion has not reached the planned schedule (divided into specific projects). In order to ensure the efficiency of the use of raised funds and reduce project investment risks, the company has moderately slowed down the "new product research and development"

and the investment progress of the "Innovation Capacity Enhancement Project" and "Marketing Network Upgrade and Remote Operation and Maintenance Service Platform Construction Project".

Description of major changes in project feasibility Not applicable

The company held the 13th meeting of the third board of directors and the ninth meeting of the third board of supervisors respectively on July 12, 2021, and reviewed and approved

The "Proposal on the Use of Raised Funds to Replace Self-raised Funds Pre-Invested in Fund-raising Projects and Issue Fees Paid" agreed that the company's use of raised funds to invest in projects was pre-invested and replaced. The raised funds of RMB 20.9641 million were used to replace the self-raised funds pre-invested in fund-raising projects, and the raised funds of RMB 371,500 were used to replace the self-raised funds that had paid issuance fees. Tianjian Accounting Firm (Special General Partnership) pre-invests the company's self-raised funds in fundraising projects

The actual investment status of the purpose was reviewed and a special verification report was issued (Tianjian Shen [2021] No. 2-357)

Use of idle raised funds to temporarily supplement working capital None

Page 12 of 17

The company held the 16th meeting of the fourth board of directors and the 15th meeting of the fourth board of supervisors on July 5, 2024, and reviewed and approved the "Proposal on the Company's Use of Part of Temporarily Idle Raised Funds for Cash Management" and agreed that the company would use the funds in total not to exceed RMB 13,0 The temporarily idle raised funds of 000,000 yuan will be used for cash management to purchase cash management products with high safety, meeting capital preservation requirements and good liquidity. The resolution is valid for 12 months from the date of review and approval by the company's board of directors, and can be used on a rolling basis within the above period.

The company held the fourth meeting of the fifth board of directors and the fourth meeting of the fifth board of supervisors on July 3, 2025, and reviewed and approved the "Cash Management of Idle Raised Funds and Investment in Related Products"

"Proposal on the Company to Use Part of Temporarily Idle Raised Funds for Cash Management", agreeing that the company will use temporarily idle raised funds with an amount not exceeding RMB 38 million for cash management to purchase cash management products that are highly safe, meet capital preservation requirements, and have good liquidity. This resolution is valid for 12 months from the date of review and approval by the company's board of directors, and can be used on a rolling basis within the above period.

In 2025, the company will use idle raised funds for cash management (purchasing capital-guaranteed financial products) in accordance with the above resolution. As of December 31, 2025, there are still 20 million yuan of capital-guaranteed financial products that have not expired.

Use of excess raised funds to permanently replenish working capital or repay bank loans Not applicable

The company's 2024 Annual General Meeting of Shareholders passed the "Proposal on the Change, Closing and Extension of the Company's Raised Fund Investment Projects and the Permanent Replenishment of Working Capital with the Surplus Raised Funds", agreeing that the company will change the total investment of the raised fund investment project "Technical Transformation and Production Capacity Expansion Project of the Medical Testing Equipment and Supporting Reagent Consumables Production Base" from 81.5908 million yuan. The total amount of investment in the project completion and "new product research and development and innovation capability improvement project" will be adjusted from 108.3233 million yuan to 75.0878 million yuan. At the same time, the remaining funds raised after the optimization and adjustment of the above two investment projects will be used to permanently replenish the company's working capital (the specific amount shall be based on the balance of the special account on the day of fund transfer). The main reason for the closing of the "Technical Transformation and Capacity Expansion Project of the Production Base of Medical Testing Equipment and Supporting Reagent Consumables" and the reduction of the investment amount: According to changes in the macroeconomic situation, industry development, downstream market demand and other conditions in recent years, combined with the company's overall development strategy, the amount of the balance of publicly raised funds and the reasons for its formation. The company believes that the existing production base has been completed and the factory has been invested in the production line technology upgrading and transformation using the raised funds in the early stage. The company's production capacity reserves are sufficient to meet the company's existing and long-term future business production capacity. Therefore, the company plans to change the construction content of the project and no longer use the raised funds to invest in new civil construction and other equipment for the production capacity expansion project.

The main reason for the reduction of the "New Product R&D and Innovation Capacity Improvement Project": due to changes in the downstream market environment, the company re-planned its R&D strategy and specific R&D projects. Accordingly, some of the R&D projects in the project were adjusted from the original independent R&D to seeking technical cooperation with third parties, and the investment amount of the project funds raised was reduced by RMB 33.2355 million.

The above two projects raised a total of RMB 88.6269 million in remaining funds, which will be transferred to the company's general account on June 30, 2025 to permanently supplement the company's liquidity.

Page 13 of 17

Other uses of raised funds None

[Note 1] The company held the second meeting of the fifth board of directors and the second meeting of the fifth board of supervisors on April 28, 2025, and reviewed and approved the "Proposal on the Change, Closing and Extension of Investment Projects with Raised Funds and the Use of Surplus Raised Funds to Permanently Supplement Working Capital", and agreed that the company would postpone the date when new product research and development and innovation capability improvement projects, marketing network upgrades and remote operation and maintenance service platform construction projects reach the scheduled usable state, all from June 2025 to December 2026.

[Note 2] The technical transformation and production capacity expansion project of the medical testing equipment and supporting reagent consumables production base has been completed. The main construction content of this investment project is to improve the company's existing production capacity. Therefore, the benefits achieved this year are calculated based on the proportion of the fixed asset investment in the project to the company's total fixed assets * net profit

Page 14 of 17

Project

marketing network marketing network

Marketing

Upgrade and go far Upgrade and go far Aiwei Technology

and service

Cheng Yun Maintenance Service Cheng Yun Maintenance Service Co., Ltd. Changsha 1,966.57 1,966.57 647.05 1,617.40 82.24 2026.12.31 Not applicable Not applicable No 2022.1.24 2022.2.16 Service category

service platform construction service platform construction company

Project

Set up project Set up project

Total 12,634.43 12,634.43 1,815.86 10,491.60 - - - - - -

Changes in January 2022

(1) Reason for change:

In order to enhance the strength of independent research and development and technological innovation, enhance the company's core competitiveness, further enrich the company's product line, form new profit growth points, and rapidly expand the company's operating scale and profitability, the company plans to develop biochemical immunity, molecular diagnosis, blood analysis, pathological diagnosis, POCT based on the original key common technology research of "Automation of Medical Microscope Morphological Inspection Based on Machine Vision Technology" and the continuous development of existing related instruments and reagent consumables such as urine testing, feces testing, reproductive tract secretion testing, etc. Conduct research and development of new projects, new technologies, and new products in testing, smart medical and other fields, and formulate corresponding new product research and development plans. Since the investment in the development of the above-mentioned new projects, new technologies, and new products is relatively large, and will gradually enter the implementation stage in the near future, therefore, taking into account the demand for capital investment in new R&D projects and the efficiency of the use of raised funds, and in order to speed up the R&D progress of new projects, new technologies, and new products, further shorten the R&D cycle, support the rapid implementation of R&D results, and improve the company's response to market demand, the company plans to adjust the infrastructure investment such as the construction of the R&D center building that was planned to be invested with raised funds in the original raised investment project to R&D investment in new projects, new technologies, and new products.

(2) Decision-making process:

Reasons for changes, decision-making procedures and information disclosure

The company held the third meeting of the fourth board of directors on January 24, 2022, and reviewed and approved the "Company's Proposal on Changes and Extensions of Some Fund-raising Projects": 1) The company plans to adjust the "R&D Center Exposure Situation Explanation of the Fund-raising Project" (divided into specific fundraising projects)

"Grade Construction Project" construction content, the investment in infrastructure such as the construction of the R&D center building planned to be invested using the raised funds in the project will be adjusted into R&D investment in new projects, new technologies, and new products. The total investment amount of the project was adjusted from 72.873 million yuan to 108.3233 million yuan, all of which was invested by raised funds. At the same time, based on the actual situation after the project implementation content is changed, it is planned to change the project name to "New Product Research and Development and Innovation Capability Improvement Project".

The company plans to adjust the construction content of the fundraising project "Marketing Network Upgrade and Remote Operation and Maintenance Service Platform Construction Project" and reduce the investment amount in the project such as office space purchase and decoration. The investment amount of the project raised funds will be reduced from 55.116 million yuan to 19.6657 million yuan. All the raised funds of RMB 35.4503 million after the reduction of the project were invested in the "new product research and development and innovation capability improvement project." On February 16, 2022, the company's first extraordinary shareholders' meeting reviewed and approved the proposal.

(3) Information disclosure:

In response to the above changes in fundraising projects, the company made an announcement on the website of the Shanghai Stock Exchange on January 25, 2022, with the announcement number: 2022-002.

Changes in April 2025

(1) Reason for change:

Page 16 of 17

Technical transformation and production capacity expansion project of the production base of medical testing equipment and supporting reagent consumables: Based on changes in the macroeconomic situation, industry development and downstream market demand, the company believes that the existing production base has built a factory. After using the raised funds to invest in the production line technology upgrade and transformation in the early stage, its production capacity reserves are sufficient to meet the company's current and long-term business needs in the future. Therefore, the company has changed the construction content of the raised investment project and will no longer use the raised funds for new civil construction and other equipment investment in the production capacity expansion project. The total investment amount of funds raised for the project was reduced by RMB 50 million, and the project was closed. The remaining raised funds after the reduction will be used to permanently replenish working capital.
New product research and development and innovation capability improvement project: Due to changes in the downstream market environment, the company has re-planned its research and development strategy and specific research and development projects. Accordingly, some of the research and development projects in this project have been adjusted from the original independent research and development to seeking technical cooperation with third parties. The investment amount of the project raised funds has been accordingly reduced by 33.2355 million yuan. The remaining raised funds after the reduction will be used to permanently replenish working capital.

(2) Decision-making process:

The company held the second meeting of the fifth board of directors and the second meeting of the fifth board of supervisors on April 28, 2025, and reviewed and approved the "Proposal on the Change, Closing and Extension of Investment Projects with Raised Funds and the Permanent Replenishment of Liquidity with Surplus Raised Funds", and agreed that the company will raise funds to The total investment of the fund-raising investment project "Technical Transformation and Production Capacity Expansion Project of Medical Testing Equipment and Supporting Reagents and Consumables Production Base" was changed from 81.5908 million yuan to 31.5908 million yuan, and the project was closed as a "new product research and development and innovation capability improvement project" The total investment was adjusted from RMB 108.3233 million to RMB 75.0878 million. At the same time, the remaining raised funds of RMB 88.6269 million after the optimization and adjustment of the above two investment projects were used to permanently replenish the company's liquidity. On May 23, 2025, the company's 2024 annual shareholders meeting reviewed and approved the proposal.

(3) Information disclosure:

In response to the above changes in fundraising projects, the company disclosed it on the Shanghai Stock Exchange website (www.sse.comcn) on April 29, 2025, with the announcement number: 2025-011.

As of December 31, 2025, the construction of the "New Product Research and Development and Innovation Capability Improvement Project" and "Marketing Network Upgrade and Remote Operation and Maintenance Service Platform Construction Project" have not reached the planned progress. The main reasons are: due to the circumstances and reasons for the upstream and downstream failure to meet the planned progress.

Due to changes in the market environment, in order to ensure the efficiency of the use of raised funds and reduce project investment risks, the company has moderately slowed down the "new product research and development and innovation capability improvement projects" and "marketing network upgrade and remote operation and maintenance service platform (divided into specific fundraising projects)"

construction project” investment progress. In the future, the company will comprehensively consider various internal and external factors, actively promote the progress of fundraising projects, and improve the efficiency of the use of raised funds.

The feasibility of the project after the change has changed significantly

Not applicable

Description of changing circumstances

Page 17 of 17